SLS SELLAS Life Sciences Group Inc.

0.81
0  0%
Previous Close 0.81
Open 0.82
Price To Book 6.75
Market Cap 20390427
Shares 25,176,475
Volume 105,726
Short Ratio
Av. Daily Volume 356,232

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Waiting on further guidance from FDA regarding future development - likely 1H 2019.
NeuVax in combination with Herceptin
Breast cancer - 1+/2+
Phase 1/2 interim analysis due 1Q 2020.
Galinpepimut-S and Keytruda (pembrolizumab)
Solid tumors
Phase 3 trial planned for 3Q 2019 with interim data due 4Q 2020.
Galinpepimut-S
Acute Myeloid Leukemia (AML)
Phase 1/2 presentation due ASCO June 2018. 1-year PFS rate was 64% in the ITT group.
Galinpepimut-S and nivolumab
Ovarian cancer

Latest News

  1. The Daily Biotech Pulse: Axovant Doses First Patient In Gene Therapy Trial, Agile Resubmits NDA, ADMA Prices Offering
  2. SELLAS Life Sciences Provides Business Update and Reports First Quarter 2019 Financial Results
  3. SELLAS Life Sciences Group and World-Renowned Cancer Center to Study Galinpepimut-S (GPS) in Combination with Nivolumab in Patients with Malignant Pleural Mesothelioma (MPM)
  4. SELLAS Life Sciences Reports 2018 Financial Results and Provides Business Update
  5. SELLAS Life Sciences Announces Presentation of Final Data Analysis from Phase 2b Study of Nelipepimut-S Plus Trastuzumab at the 2019 ASCO-SITC Clinical Immuno-Oncology Meeting
  6. Sellas Reviews Strategic Options To Fund Clinical Development Programs
  7. SELLAS Life Sciences Announces Review of Strategic Alternatives
  8. SELLAS Life Sciences Provides Galinpepimut-S and Nelipepimut-S Program Update
  9. SELLAS Life Sciences to Present at the 2019 BIO CEO & Investor Conference
  10. SELLAS Life Sciences Provides Update on Late-Stage Immunotherapy Clinical Development Pipeline
  11. SELLAS Life Sciences Announces Additional Positive Triple Negative Breast Cancer (TNBC) Subgroup Data from Phase 2b Study of Nelipepimut-S Plus Trastuzumab  at the 2018 San Antonio Breast Cancer Symposium
  12. SELLAS to Present Further Correlative Data from Phase 2b Trial of NeuVax + Herceptin® at the 2018 San Antonio Breast Cancer Symposium
  13. SELLAS Life Sciences Announces Expedited Development Path for Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) Following Feedback from FDA
  14. SELLAS Life Sciences Announces Completion of Enrollment in Phase 2 Randomized Controlled Clinical Study of Nelipepimut-S Plus Trastuzumab in High-risk, High-expression HER2 Breast Cancer Patients
  15. SELLAS Life Sciences Provides Business Update and Reports Third Quarter 2018 Financial Results
  16. SELLAS Life Sciences Settles Lawsuit and Prepares to Advance Galinpepimut-S, Analysts Review
  17. Health Care Stocks Making Moves On Friday; Premier Health Group, Inc. (PHGRF) (PHGI), Sellas Life Sciences, Teladoc
  18. SELLAS Life Sciences Announces Additional Data Showing Consistent Clinical Effect Across HLA Allele Subgroups in Triple Negative Breast Cancer (TNBC) Patients Treated with Nelipepimut-S Plus Trastuzumab Presented at the Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting
  19. SELLAS Life Sciences Announces Settlement of Counterclaims Against JGB (Cayman) Newton, Ltd. for $6.6 Million Payment by JGB
  20. SELLAS Life Sciences to Provide Third Quarter 2018 Financial Results and Corporate Update on November 15, 2018